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Abstract
Background Treatment response for psoriasis is typically evaluated using clinical scores. However, patients can
relapse after clinical clearance, suggesting persistent inflammation. Dermoscopy, reflectance confocal microscopy
(RCM) and optical coherence tomography (OCT) can non-invasively improve treatment response assessment.
Objectives To compare the clinical and non-invasive microscopic features in a psoriatic target lesion treated with clo-
betasol cream or calcipotriol/betamethasone dipropionate foam (Cal/BD foam).
Methods Prospective, unicentric, open, randomized clinical trial comparing clinical data [total clinical score (TCS)] and
microscopic data (dermoscopy, RCM and OCT) in psoriasis patients treated with clobetasol or Cal/BD foam.
Results We included 36 adult patients (22 men). At week 4, more patients treated with Cal/BD foam achieved TCS ≤1
than with clobetasol (63.2% vs. 18.8%, P = 0.016). Treatment satisfaction was higher with Cal/BD foam (P < 0.03).
Microscopically, Cal/BD foam induced more reduction in epidermal thickness at week 4 (P < 0.049). Dilated horizontal
blood vessels were more common with clobetasol than with Cal/BD foam at week 8 (69.2% vs. 31.2%, P = 0.159). If epi-
dermal hyperplasia was noted at baseline, the response was poorer with clobetasol (P = 0.029).
Limitations Small sample size, open study, imaging sampling bias.
Conclusion Cal/BD foam is more effective than clobetasol, has better patient satisfaction and induces greater reduc-
tion in the hyperkeratosis/acanthosis, regardless of baseline epidermal hyperplasia.
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Introduction
The effectiveness of topical treatments for plaque psoriasis is
typically evaluated using clinical scores such as psoriasis area
severity index (PASI) or physician global assessment (PGA).
However, sometimes patients relapse short after withdrawing
their treatments besides showing clinical clearance using these
scores, thus suggesting persistence of underlying inflammation
not visible to the naked eye. In addition, classical topical treat-
ments such as potent corticosteroids can lead to side-effects if
IRB: This study was performed under the Hospital Clınic de
Barcelona’s Ethics Committee-approved protocol number
HC-ENS-2017-01.
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used for long periods of time, which are difficult to anticipate
when using conventional clinical examination. In this sense,
ancillary tests, ideally non-invasive ones, may help evaluate the
treatment response and assess the side-effects.
Non-invasive imaging technologies such as dermoscopy,
reflectance confocal microscopy (RCM) or optical coherence
tomography (OCT) have been extensively used to diagnose skin
cancers1–6 and to assess skin cancer treatment responses.7–9 Since
these technologies allow the visualization of structures not visi-
ble with the naked eye and have direct histopathological corre-
lates,10–12 they seem ideal to better define the effective clearance
and assess the side-effects in psoriatic patients undergoing topi-
cal treatments.
The current study aims to describe and compare the clinical
and non-invasive microscopic features in a psoriatic target lesion
in a prospective cohort of psoriatic patients before, during and
after the treatment with two topical treatments for mild to mod-
erate psoriasis: clobetasol cream vs. a fixed combination of cal-
cipotriol/betamethasone dipropionate foam (Cal/BD foam).
Materials and methods
After approval of the Ethics Committee of Hospital Clınic de
Barcelona, from March 2018 to March 2019, we prospectively
included consecutive patients with mild to moderate plaque pso-
riasis who were amenable to be treated with topical treatments
[total body surface area (BSA) <10%]. Inclusion and exclusion
criteria are found in Tables S1 and S2.
After written informed consent, patients were randomized 1:1
using a predefined randomization table to apply clobetasol cream
0.5 mg/g (Clovate; Industrial Farmaceutica Cantabria, San-
tander, Spain) once daily 2–4 weeks according to clinical response
or Cal/BD foam 50 µg/g + 0.5 mg/g (Enstilar; LEO Pharma,
Copenhagen, Denmark) once daily for 4 weeks. The treatment
arm was not blind since the researchers randomizing and following
the patients (OY, NM), and the patients knew the treatment. These
same researchers decided whether it was necessary to continue or
stop the treatment based on clinical response and/or the presence
of adverse events. Patients were evaluated at baseline, at week 2, at
week 4 and at week 8 (1 month without treatment) (Fig. S1).
Clinical evaluation
We obtained high-resolution clinical pictures (Canon Powershot
G15, Canon Inc, Tokyo, Japan) of the patient’s most severe pla-
que at baseline. Later, pictures were obtained at the same location
using the same camera settings and illumination parameters. Fur-
thermore, based on these images, we determined the Total Clini-
cal Score (TCS), which grades erythema (0–3), induration (0–3)
and scaling (0–3). The image evaluation was performed at the end
of the study by three investigators (SE, LC and SZ) who were
blinded to the treatment arm. The study primary end point was
to achieve a TCS ≤1 at week 4. Adverse events were also noted,
and if they posed a risk to the patient, treatment was
discontinued. At the last visit, patients were also asked to rate
their treatment satisfaction using a Visual Analogic Scale from 0
to 10, being 0 very dissatisfied and 10 extremely satisfied.
Microscopic evaluation
We obtained dermoscopic pictures using DermLite Foto (3Gen,
San Juan Capistrano, CA, USA), handheld RCM images (Vivas-
cope 3000; MAVIG/Caliber ID, Rochester, NY, USA) and
dynamic OCT image rasters (Vivosight, Michelson Diagnostics,
Maidstone, UK) at the centre of the target lesion. The images
were later evaluated by three investigators (SE, LC and SZ), who
did not collect the images, and were blinded to the treatment
arm. The imaging features evaluated are summarized in Table S3
and included quantitative variables and semiquantitative vari-
ables (0–3). The definition of the features evaluated can be
found elsewhere.13
Sample size calculation and statistical analysis
A sample size of 16 patients in each group was determined in
order to detect differences of two units (SD = 2.25) in the
reduction of plaque psoriasis descriptors (TCS) between both
groups. We considered a power of 80% and a significance level
of 0.05. Considering a loss of evaluable individuals (loss of fol-
low-up, missing data, etc.) of 10%, a total of 18 patients in each
group (36 patients in total) were deemed necessary to achieve
statistically significant results.
Descriptive statistics were used to describe the distribution of
clinical and microscopic data. Fisher’s exact test was used to
compare qualitative variables. Mann–Whitney test was used to
compare quantitative and qualitative variables that were not
normally distributed. Two-sided P values <0.05% were consid-
ered statistically significant. Analyses were performed using SPSS
Statistics v. 22 (IBM Corporation, Armonk, NY, USA).
Results
Cohort characteristics
We included 36 patients (22 men, 14 women) with a median age
of 47.5 years (range 28–80 years) (Table 1). The median weight,
height, abdominal perimeter and body mass index were 75.5 kg
(range 49–103 kg), 170 cm (range 152–185 cm), 96 cm (range
65–117 cm) and 24.94 kg/m2 (range 18.81–38.1 kg/m2), respec-
tively. Regarding treatments in the previous 4 months, three
patients had only used emollients, two had received photother-
apy, and 30 patients used one or more topical treatments.
The majority of the target lesions were located on the elbows
(n = 15) followed by the buttocks/lumbosacral area (n = 8), the
abdomen (n = 5), the knees (n = 4), other parts of the legs
(n = 3) and the back (n = 1). One patient was withdrawn from
the study due to pregnancy, although the patient later delivered
a healthy baby besides incidental application of topical Cal/BD
foam for less than a week. In eight occasions, patients missed a
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follow-up appointment, and among them, three did not come to
the last follow-up appointment and were considered lost to fol-
low-up. One patient in the clobetasol arm applied the treatment
for 2 weeks due to complete response (TCS = 0) whereas the
remaining patients applied the treatment for 4 weeks.
Clinical results
When assessing the lesions at baseline, there were no statistical
differences in the median TCS before treatment between the clo-
betasol group (median 4.5) and the Cal/BD foam group (median
5) (P = 0.235), making the two groups comparable. Compared
to the baseline TCS evaluation, at 4 weeks, there was a greater
TCS reduction using Cal/BD foam compared to clobetasol (80%
vs. 43.4% reduction; median TCS 1 vs. 3, P < 0.022) (Fig. 1). At
week 4, there was a significant difference in the number of
patients who achieved the study primary end point (TCS ≤ 1):
63.2% in the Cal/BD foam group vs. 18.8% in the clobetasol
group (P = 0.016) (Fig. 2). At week 8, the TCS increased in both
groups but remained lower with Cal/BD foam: median TCS with
Cal/BD 1.5 vs. median TCS with clobetasol 3 (P = 0.568)
(Fig. 1). No severe adverse events were noted during the study.
Regarding the adverse events related to the treatment, only itch
at the application site was reported in two patients applying Cal/
BD foam and in one applying clobetasol. Four patients in the
Cal/BD foam group reported that the treatment was messy to
apply. However, patient satisfaction with the treatment was sig-
nificantly higher with Cal/BD foam compared to clobetasol [me-
dian 9, mean 9.06 (range 7–10) vs. median 7, mean 6.5 (range 1–
10), P < 0.03; Fig. S2].
Microscopic results
Cal/BD foam induced a faster and greater reduction in epider-
mal thickness at weeks 2, and four identified with OCT
(P < 0.049, Fig. 3a). Inflammatory cells identified with RCM
increased with Cal/BD foam at week 2 and later decreased, being
lower than clobetasol after week 4 (P < 0.05, Fig. 3b).
Linear blood vessels were identified using dermoscopy in
28.6% of clobetasol cases vs. 37.5% of Cal/BD foam cases at
week 8 (P = 0.709). When assessing these vessels with RCM and
OCT, we identified dilated horizontal vessels in the upper dermis
(vessels >70 µm) in 69.2% of clobetasol cases vs. 31.2% of Cal/
BD foam cases at week 8 (P = 0.159, Fig. 4).
Regarding the microscopic features that were associated with
sustained response (week 8), we saw that if epidermal hyper-
plasia was noted at baseline, the response was poorer with clobe-
tasol (P = 0.029), whereas the presence or absence of epidermal
hyperplasia did not affect the treatment response at week 8 with
Cal/BD foam (P = 0.542; Fig. 5). Although it did not achieve
statistical significance, we observed similar results regarding the
presence of scale on dermoscopy; when important scaling was
observed at baseline, the lesions would be less likely to continue
clear at week 8 with clobetasol (11 not clear vs. 2 clear,
P = 0.489), whereas with Cal/BD foam, more cases with intense
scaling on dermoscopy maintained a TCS ≤1 at week 8 (10 not
clear vs. 7 clear, P = 0.211).
We did not see significant differences between both treat-
ments regarding the changes in parakeratosis, spongiosis, irregu-
lar epidermis or dilated vertical blood vessels.
Table 1 Baseline demographics and clinical characteristics of
each group
Median Clobetasol Cal/BD foam
Age 49.5 years 43 years
Weight 75.7 kg 73 kg
Height 170 cm 171 cm
Abdominal perimeter 96 cm 93 cm
BMI 24.94 kg/cm2 24.91 kg/cm2



















































Figure 1 Line graphs showing the evolution of total clinical score
(TCS) in both treatment groups. Panel (a) shows the median TCS








































Not clear (TCS>1)P = 0.016
Figure 2 Graph bar showing cases achieving the study primary’s
end point (TCS ≤ 1) at W4 (orange bars) in both treatment groups.
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Discussion
Our results suggest that Cal/BD foam is more effective than clo-
betasol after 4 weeks of treatment, shown both clinically and
microscopically, is potentially safer than clobetasol by inducing
less iatrogenic vessels and has higher patient satisfaction. Clini-
cally, we have shown that Cal/BD foam induces a faster response
compared to clobetasol cream with a mean reduction of 80% vs.
43.4% (P < 0.022) of the TCS at 4 weeks. Additionally, more
patients achieved total or almost total lesion clearance
(TCS ≤ 1) at week 4 with Cal/BD foam compared to clobetasol
(63.2% vs. 18.8%, P = 0.016). Furthermore, more patients
maintained a TCS ≤1 at week 8 (1 month without treatment) in
the Cal/BD foam arm, although it did not reach statistical signif-
icance (P = 0.568).
Regarding the microscopic findings, we identified a faster
reduction in the scaling observed with dermoscopy when using
Cal/BD foam, as well as a faster reduction in the hyperkeratosis/
acanthosis in OCT with Cal/BD foam. This correlates well with
another of our findings which shows that if more epidermal
hyperplasia was noted with OCT at baseline, the lesions would
be less likely to respond with clobetasol. This suggests that clobe-
tasol cream may not penetrate deep enough in the psoriatic pla-
que if this is thick, whereas Cal/BD foam can be still effective
regardless of the plaque thickness, even though the vehicle is a
foam. The reason for this increased effectivity may be that the
current formulation of Cal/BD foam is a novel aerosol foam
which when sprayed does not crystalize and allows the rapid
evaporation of propellants thus leaving a supersaturated layer of
Cal/BD on the skin.14 In fact, previous studies have shown that
Cal/BD penetrates deeper and exerts a more intense action when
formulated in this novel foam compared to the same concentra-
tions of Cal/BD but formulated as an ointments.15–17
Another interesting microscopic finding we identified was
related to the presence of dilated horizontal vessels at the end of
the study. Although our sample size is small and the results did
not reach statistical significance, our results suggest that clobeta-
sol induces more dilated linear vessels compared to Cal/BD foam
at week 8 (69.2% of clobetasol cases vs. 31.2% of Cal/BD foam
cases, P = 0.159). Hence, OCT and RCM allow the visualization
of these dilated vessels better than the naked eye or dermoscopy.
These vessels indicate the potential iatrogenic effect of corticos-
teroids,18,19 thus suggesting non-invasive microscopic methods
may be necessary to assess the early onset of adverse events
related to treatment.
Interestingly, we have also seen a temporary increase in the
numbers of inflammatory cells with RCM when using Cal/BD
foam after 2 weeks of treatment (Fig. 3b). An explanation for
this finding could be that Cal/BD induces an increase in CD8+
lymphocytes, which restores the CD4+ and CD8+ lymphocyte
epidermal counts thus normalizing the skin microenviron-
ment.20 However, to confirm this hypothesis, biopsies may have
been needed to perform immunohistochemical studies. Another
possible explanation for this increase may be due to a certain
degree of irritation related to the vehicle (a foam) or to cal-
cipotriol itself.14 In fact, two patients reported itch at the appli-
cation site of Cal/BD foam. Nevertheless, this did not seem
relevant and did not reduce treatment adherence since patients
continued to apply the treatment and actually reported higher
patient satisfaction with Cal/BD foam compared to clobetasol
(Fig. S2). This increase in inflammatory cells was transient, and
later, the inflammatory cell counts decreased to levels lower than
with clobetasol. Hence, probably this early increase in inflamma-
tory may correlate with a better treatment response, suggesting
that microscopic data may not only improve the detection of
early adverse events, but can better grade the treatment
response.
Non-invasive microscopic assessment using tools such as der-
moscopy, RCM or OCT has been used extensively in the fields of
dermato-oncology and more recently to diagnose inflammatory
dermatoses21–24 and to grade treatment response.13,25 The
advantage of these technologies is that they allow a fast assess-
ment without the need of being invasive. Dermoscopy uses a
magnifying lens (commonly 109) which allows the visualization
of structures not visible to the naked eye but not reaching the
cellular level.12 RCM uses a near-infrared light laser which allows
the visualization of en face images with cellular resolution;26,27
however, because of this high resolution, RCM can only image
up to ~250 µm (superficial dermis). OCT uses also a laser light
source which allows a deeper penetration, up to 1 cm, but at the
cost of a worse resolution. OCT can assess the architecture and






































































Figure 3 Line graphs showing the evolution of relevant micro-
scopic findings. Panel (a) shows the evolution of the epidermal
thickness measured with OCT. Panel (b) shows the evolution of
inflammatory cells identified using RCM.
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Figure 4 Clinical, dermoscopic, RCM and OCT images at week 8 in a case treated with clobetasol (panel a) and in a case treated with
Cal/BD foam (panel b). (a) Clobetasol case at week 8 showing TCS 2, linear vessels (arrows) and scale (arrowheads) on dermoscopy, and
parakeratosis (arrowheads) and dilated horizontal blood vessels (arrows) on RCM and OCT. (b) Cal/BD foam case at week 8 showing
TCS 1, linear (arrows) and dotted vessels (arrowheads) on dermoscopy, increased numbers of vertical dilated blood vessels (arrowheads)
and slightly dilated horizontal blood vessels (arrows) on RCM and OCT.
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As stated in the previous paragraph, the use of these imaging
technologies has some limitations; although we used different
imaging technologies to maximize the information obtained,
some degree of sampling error may have occurred, since psori-
atic plaques are typically in the range of centimetres, much larger
than the field of view of the technologies used. Nevertheless, we
tried to minimize this issue by imaging the centre of the target
lesion, although sometimes identifying the same exact area was
hard since the morphology of psoriatic plaques may change
throughout the treatment process.
Another challenge we encountered was the assessment of ves-
sels using dynamic OCT. Vessel quantification in OCT needs to
be done in the different planes and can vary depending on
anatomical factors, vasodilation due to exogenous factors (tem-
perature, elevation of the area imaged, irritation), among others.
In addition, the software does not provide an objective measure-
ment of the quantity of vessels, which makes its assessment diffi-
cult. Because of this, we started the development of an
informatics algorithm to automatically quantify the vessel den-
sity. However, this is not an easy endeavour since vessels in
dynamic OCT need to be adjusted by the blood flow in healthy
skin, which can also change depending on the anatomic area.
Additionally, dynamic OCT induces a ‘shadow’ artefact in which
under a given vessel the device cannot assess correctly the blood
flow. Another aspect to take into consideration is that vessels need
to be measured at the same vertical plane to be compared, but
since psoriatic plaques changed their thickness, comparison over
time was challenging. This may explain why we have identified a
tendency in increased dilated blood vessels with clobetasol, but
the difference did not reach statistical significance. Another limi-
tation which can also explain the latter includes a small sample
size, since it was calculated to evaluate differences in the TCS.
Another limitation of our study is that the patients and investiga-
tors acquiring the images were not blind to the treatment and that
although the analysis of the images was performed by three evalu-
ators who were blind to the treatment arm, subjective interpreta-
tion of the images may have impacted the results.
Regarding the last point, efforts have been made to provide
objective, automated or semi-automated image assessment using
artificial intelligence (AI). Currently, different AI algorithms
have shown to have high diagnostic accuracy to diagnose multi-
ple dermatoses, at the same level or superior to dermatolo-
gists.30,31 Thus, it seems intuitive that AI algorithms may allow
an objective accurate objective evaluation in psoriasis. Several
studies have attempted to do so by using colour calibration,32
and in fact semi-automated and automated PASI calculation
algorithms have been developed using calibrated images
acquired in order to provide more objective disease quantifica-
tion than manual PASI or PGA calculations performed by physi-
cians.33–35 Hence, such methods could also be applied in other
fields of dermatological imaging in order to improve disease
quantification and to better determine response and manage-
ment of side-effects.36,37
Conclusion
To sum up, we have shown that Cal/BD foam is more effective
than clobetasol cream after 4 weeks of treatment, has better
patient satisfaction than clobetasol and induces a faster and
greater reduction in the hyperkeratosis/acanthosis, regardless of
the initial epidermal hyperplasia status. Our results also suggest
that clobetasol may induce more iatrogenic telangiectasias com-
pared to Cal/BD foam. However, our sample was small and lacks
automated measurements. Hence, future studies using AI and
multimodal imaging methods are necessary to obtain objective
data regarding treatment response and prediction of early
adverse events in psoriatic patients treated with topical
treatments.
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Supporting information
Additional Supporting Information may be found in the online
version of this article:
Table S1. Study’s inclusion criteria.
Table S2. Study’s exclusion criteria.
Table S3. Description of the microscopic variables analyzed in
this study.
Figure S1. Scheme of the treatment visits.
Figure S2. Box plot comparing patient satisfaction with clobeta-
sol vs. calcipotriol/betamethasone dipropionate foam, showing
an overall higher satisfaction with the latter.
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